# (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Source: https://onco.cc/trials/nct05607004/  
OnCo record `nct05607004` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of (Z)-endoxifen in HR-positive / HER2-negative breast cancer, run by Atossa Therapeutics, Inc., active and no longer recruiting.

## Summary

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer is a phase 2 interventional study registered as NCT05607004 by Atossa Therapeutics, Inc., with 87 participants enrolled, started 2023-02-14 and due to reach its primary completion in 2026-11. Interventions recorded: (Z)-endoxifen and goserelin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05607004
- Phase: 2
- Setting: A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer
- Sponsor: Atossa Therapeutics, Inc.
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT05607004: https://clinicaltrials.gov/study/NCT05607004

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- companies: [Atossa Therapeutics](https://onco.cc/companies/atossa-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05607004.json